Medical device company MicroPort Orthopedics has launched its EVOLUTION Revision tibial system and EVOLUTION BioFoam tibia.
Designed by surgeons from Europe, Asia, Canada and the US, the new tibial system is a revised version of the firm's Medial-Pivot knee system.
The revised system is expected to provide intra-operative flexibility for individual anatomic patient needs, such as fixation problems due to poor bone stock, and maintain the kinematic benefits of the Medial-Pivot.
MicroPort Orthopedics president Aurelio Sahagun said: “MicroPort Orthopedics continues to grow its product portfolio with a steady cadence of product launches.
“These product launches demonstrate our commitment to help improve patient outcomes by giving surgeons a broad array of choices that allow them to treat their patients.
"We are excited to bring the benefits of the Medial-Pivot design to a revision system.”
The new BioFoam tibia is launched as a part of the EVOLUTION Medial-Pivot cement-less system to complement the existing EVOLUTION porous femoral component.
Based on the existing ADVANCE BioFoam tibia, the new device is designed to combine the Medial-Pivot benefits and the early fixation advantages, while meeting the long-term demands of young and active patients.
The ADVANCE BioFoam tibia is reported to have 98% survivorship at two years.
Based in Tennessee, US, MicroPort Orthopedics develops, produces and distributes orthopaedic reconstructive products.
Its US manufacturing and logistics capabilities provide hip and knee products in more than 60 markets, such as EMEA, Japan, Latin America and China.